Ying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Liu has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Ke Li
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
11 shared publicationsShuning Xu
Department of Digestive Diseases, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
10 shared publicationsCheng Zhang
Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China
6 shared publicationsLei Qiao
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
6 shared publicationsDanyang Li
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
5 shared publicationsQun Li
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
4 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1917046
Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial
Background: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a characteristic cutaneous adverse event associated with immune checkpoint inhibitors. This study compared two prophylactic thalidomide doses to identify the more promising dose for further evaluation. Methods: In this multicenter, randomized clinical trial, patients with advanced esophageal squamous cell carcinoma or non-small cell lung cancer (NSCLC) were randomly assigned to receive thalidomide 50 mg/day (Group A) or 100 mg/day (Group B) during first-line treatment with camrelizumab plus standard chemotherapy. The primary endpoint was overall RCCEP incidence; secondary endpoints included grade ≥3 RCCEP, median time to RCCEP onset, week 6 and week 9 RCCEP incidence, and safety. Results: A total of 72 patients were randomized. RCCEP occurred in 12 of 36 patients (33.3%) in Group A and 9 of 36 patients (25.0%) in Group B. RCCEP incidence at week 6 was 13.9% in Group A and 19.4% in Group B, and by week 9 was 25.0% and 19.4%, respectively. No grade ≥3 RCCEP occurred; all first RCCEP events were grade 1, with 1 grade 2 event reported in Group A. Among patients who developed RCCEP, median onset time was 1.49 and 1.31 months, respectively. Thalidomide-related adverse events occurred in 22.2% and 41.7% of patients, and grade 3 or higher thalidomide-related adverse events occurred in 8.3% and 22.2%, respectively. Serious adverse events occurred in 11.1% and 13.9% of patients, respectively. Conclusion: Thalidomide 100 mg/day met the prespecified incidence-based dose-selection criterion compared with 50 mg/day but was associated with a higher incidence of grade 3 or higher toxicity. Further controlled evaluation is warranted. Clinical trial registration: https://clinicaltrials.gov/study/NCT06231680 , identifier NCT06231680.
- 16 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1917046
Open AccessThalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial
Background: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a characteristic cutaneous adverse event associated with immune checkpoint inhibitors. This study compared two prophylactic thalidomide doses to identify the more promising dose for further evaluation. Methods: In this multicenter, randomized clinical trial, patients with advanced esophageal squamous cell carcinoma or non-small cell lung cancer (NSCLC) were randomly assigned to receive thalidomide 50 mg/day (Group A) or 100 mg/day (Group B) during first-line treatment with camrelizumab plus standard chemotherapy. The primary endpoint was overall RCCEP incidence; secondary endpoints included grade ≥3 RCCEP, median time to RCCEP onset, week 6 and week 9 RCCEP incidence, and safety. Results: A total of 72 patients were randomized. RCCEP occurred in 12 of 36 patients (33.3%) in Group A and 9 of 36 patients (25.0%) in Group B. RCCEP incidence at week 6 was 13.9% in Group A and 19.4% in Group B, and by week 9 was 25.0% and 19.4%, respectively. No grade ≥3 RCCEP occurred; all first RCCEP events were grade 1, with 1 grade 2 event reported in Group A. Among patients who developed RCCEP, median onset time was 1.49 and 1.31 months, respectively. Thalidomide-related adverse events occurred in 22.2% and 41.7% of patients, and grade 3 or higher thalidomide-related adverse events occurred in 8.3% and 22.2%, respectively. Serious adverse events occurred in 11.1% and 13.9% of patients, respectively. Conclusion: Thalidomide 100 mg/day met the prespecified incidence-based dose-selection criterion compared with 50 mg/day but was associated with a higher incidence of grade 3 or higher toxicity. Further controlled evaluation is warranted. Clinical trial registration: https://clinicaltrials.gov/study/NCT06231680 , identifier NCT06231680.
- Open Access
- 4 April 2026
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1398-1405
Association of cardiovascular-kidney-metabolic syndrome with cardiovascular, cancer, and all-cause mortality among US adults: A prospective study
- 4 April 2026
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (11) , 1398-1405
Open AccessAssociation of cardiovascular-kidney-metabolic syndrome with cardiovascular, cancer, and all-cause mortality among US adults: A prospective study
- 15 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105284
Cancer-associated fibroblasts: Orchestrators of the peritoneal metastatic microenvironment
- 15 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105284
Cancer-associated fibroblasts: Orchestrators of the peritoneal metastatic microenvironment
- Open Access
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1680517
Integrative multi-omics analysis of gastric cancer evolution from precancerous lesions to metastasis identifies a deep learning-based prognostic model
Background: Gastric cancer progression involves complex interactions among tumor cells, immune components, and stromal elements within the tumor microenvironment. However, a comprehensive understanding of cellular heterogeneity, spatial organization, and cell-cell communication in gastric cancer remains incomplete. Methods: Single-cell RNA sequencing was performed on 252, 399 cells from six tissue types, spanning gastritis, intestinal metaplasia, primary tumors, adjacent normal tissue, and metastatic lesions. Integration with spatial transcriptomics enabled spatial mapping of cellular interactions. Pseudotime, cell-cell communication, and transcriptional heterogeneity analyses were conducted. Tumor stage-associated gene modules were identified using Weighted Gene Co-expression Network Analysis (WGCNA) of The Cancer Genome Atlas (TCGA) data. Finally, a deep learning-based prognostic model was developed and externally validated. Results: Our analysis revealed dynamic remodeling of the tumor microenvironment during gastric cancer progression, characterized by the expansion of dysfunctional CD8+ T cells, pro-tumorigenic fibroblasts (e.g., ITGBL1+, PI16+, and ITLN1+), and altered myeloid populations. Stromal-immune crosstalk, particularly fibroblast-driven immunosuppressive signaling, was prominent. Spatial transcriptomics revealed the colocalization of immune and stromal cells, supporting spatially organized cellular interactions. WGCNA identified a gene module (657 genes) associated with T cell, myeloid, and stromal alterations, as well as tumor stage. A deep learning model based on this gene set accurately stratified patients according to survival in both TCGA and independent validation cohorts. Risk scores were correlated with clinical features, including tumor stage and therapeutic response. Conclusions: Our integrative single-cell, spatial, and computational analysis provides a high-resolution map of gastric cancer microenvironment remodeling. We identified key stromal and immune subpopulations, extensive cellular communication networks, and spatial structures that collectively drive tumor progression and metastasis. The derived gene signature and prognostic model have the potential for clinical risk stratification and therapeutic targeting in gastric cancer.
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1680517
Open AccessIntegrative multi-omics analysis of gastric cancer evolution from precancerous lesions to metastasis identifies a deep learning-based prognostic model
Background: Gastric cancer progression involves complex interactions among tumor cells, immune components, and stromal elements within the tumor microenvironment. However, a comprehensive understanding of cellular heterogeneity, spatial organization, and cell-cell communication in gastric cancer remains incomplete. Methods: Single-cell RNA sequencing was performed on 252, 399 cells from six tissue types, spanning gastritis, intestinal metaplasia, primary tumors, adjacent normal tissue, and metastatic lesions. Integration with spatial transcriptomics enabled spatial mapping of cellular interactions. Pseudotime, cell-cell communication, and transcriptional heterogeneity analyses were conducted. Tumor stage-associated gene modules were identified using Weighted Gene Co-expression Network Analysis (WGCNA) of The Cancer Genome Atlas (TCGA) data. Finally, a deep learning-based prognostic model was developed and externally validated. Results: Our analysis revealed dynamic remodeling of the tumor microenvironment during gastric cancer progression, characterized by the expansion of dysfunctional CD8+ T cells, pro-tumorigenic fibroblasts (e.g., ITGBL1+, PI16+, and ITLN1+), and altered myeloid populations. Stromal-immune crosstalk, particularly fibroblast-driven immunosuppressive signaling, was prominent. Spatial transcriptomics revealed the colocalization of immune and stromal cells, supporting spatially organized cellular interactions. WGCNA identified a gene module (657 genes) associated with T cell, myeloid, and stromal alterations, as well as tumor stage. A deep learning model based on this gene set accurately stratified patients according to survival in both TCGA and independent validation cohorts. Risk scores were correlated with clinical features, including tumor stage and therapeutic response. Conclusions: Our integrative single-cell, spatial, and computational analysis provides a high-resolution map of gastric cancer microenvironment remodeling. We identified key stromal and immune subpopulations, extensive cellular communication networks, and spatial structures that collectively drive tumor progression and metastasis. The derived gene signature and prognostic model have the potential for clinical risk stratification and therapeutic targeting in gastric cancer.
- Open Access
- 8 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-25
Emerging role of cancer-associated fibroblasts in the premetastatic niche
In recent years, tumor metastasis has become one of the major causes of high recurrence and mortality in cancer patients. Owing to multiorgan involvement, metastatic cancers are now clinically difficult to cure and often have a very poor prognosis. In recent years, an increasing number of studies have shown that the establishment of a premetastatic niche (PMN) is necessary for tumor metastasis. Cancer-associated fibroblasts (CAFs), which are closely related to tumor development, are deeply involved in regulating PMN establishment. By regulating EVs, metabolism and other pathways, CAFs actively shape microenvironmental characteristics, including inflammation, angiogenesis, increased vascular permeability, lymphangiogenesis, immunosuppression and extracellular matrix (ECM) remodeling. With the development of single-cell sequencing technology, our understanding of the role and significance of heterogeneous CAFs in the PMN has improved. Multiple therapeutic strategies targeting CAFs in the PMN have also been developed. This article focuses on the crosstalk of different subtypes of CAFs with other stromal cells, the mechanisms by which CAFs of different origins mediate PMN formation, and the emerging cancer therapeutic strategies by which CAFs have been targeted in recent years.
- 8 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-25
Open AccessEmerging role of cancer-associated fibroblasts in the premetastatic niche
In recent years, tumor metastasis has become one of the major causes of high recurrence and mortality in cancer patients. Owing to multiorgan involvement, metastatic cancers are now clinically difficult to cure and often have a very poor prognosis. In recent years, an increasing number of studies have shown that the establishment of a premetastatic niche (PMN) is necessary for tumor metastasis. Cancer-associated fibroblasts (CAFs), which are closely related to tumor development, are deeply involved in regulating PMN establishment. By regulating EVs, metabolism and other pathways, CAFs actively shape microenvironmental characteristics, including inflammation, angiogenesis, increased vascular permeability, lymphangiogenesis, immunosuppression and extracellular matrix (ECM) remodeling. With the development of single-cell sequencing technology, our understanding of the role and significance of heterogeneous CAFs in the PMN has improved. Multiple therapeutic strategies targeting CAFs in the PMN have also been developed. This article focuses on the crosstalk of different subtypes of CAFs with other stromal cells, the mechanisms by which CAFs of different origins mediate PMN formation, and the emerging cancer therapeutic strategies by which CAFs have been targeted in recent years.
- Open Access
- 25 July 2025
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 22 (1) , 81
High dietary live microbe intake associated with reduced depressive symptoms in gastrointestinal disease patients: findings from a cross-sectional study
Depression and gastrointestinal disease are prevalent conditions that often coexist, significantly impacting daily life and productivity. Recent studies suggest a potential link between the intake of dietary live microbe and the alleviation of depressive symptoms. However, the relationship between live microbe consumption and depressive symptoms in patients suffering from gastrointestinal diseases remains unexplored. This study included participants with gastrointestinal diseases from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2018. We utilized weighted multivariate logistic regression, subgroup analyses, and restricted cubic spline (RCS) analyses to investigate the association between live microbe consumption and depression. Additionally, the eXtreme Gradient Boosting (XGBoost) algorithm was implemented to develop a predictive model for depression based on individual characteristics. Of the 2,195 individuals, 472 (21.5%) exhibited depressive symptoms (PHQ-9 ≥ 10). Our findings indicate an inverse relationship between the live microbe intake and the incidence of depression in individuals with gastrointestinal diseases. In the most comprehensively adjusted model, patients with the highest level of microbe intake exhibited a 66.1% or 52.9% reduced risk of depressive symptoms compared to those with the minimal intake. An L-shaped dose-response relationship was observed in the RCS analysis (non-linear P = 4e-04). The XGBoost model demonstrated effective prediction capabilities for depression, with an area under the curve (AUC) of 0.897 (95% CI: 0.869-0.925). This study provides evidence of an inverse, non-linear association between dietary live microbe and depression in individuals with gastrointestinal diseases, suggesting that higher intake levels may offer protective effects against depressive symptoms.
- 25 July 2025
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 22 (1) , 81
Open AccessHigh dietary live microbe intake associated with reduced depressive symptoms in gastrointestinal disease patients: findings from a cross-sectional study
Depression and gastrointestinal disease are prevalent conditions that often coexist, significantly impacting daily life and productivity. Recent studies suggest a potential link between the intake of dietary live microbe and the alleviation of depressive symptoms. However, the relationship between live microbe consumption and depressive symptoms in patients suffering from gastrointestinal diseases remains unexplored. This study included participants with gastrointestinal diseases from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2018. We utilized weighted multivariate logistic regression, subgroup analyses, and restricted cubic spline (RCS) analyses to investigate the association between live microbe consumption and depression. Additionally, the eXtreme Gradient Boosting (XGBoost) algorithm was implemented to develop a predictive model for depression based on individual characteristics. Of the 2,195 individuals, 472 (21.5%) exhibited depressive symptoms (PHQ-9 ≥ 10). Our findings indicate an inverse relationship between the live microbe intake and the incidence of depression in individuals with gastrointestinal diseases. In the most comprehensively adjusted model, patients with the highest level of microbe intake exhibited a 66.1% or 52.9% reduced risk of depressive symptoms compared to those with the minimal intake. An L-shaped dose-response relationship was observed in the RCS analysis (non-linear P = 4e-04). The XGBoost model demonstrated effective prediction capabilities for depression, with an area under the curve (AUC) of 0.897 (95% CI: 0.869-0.925). This study provides evidence of an inverse, non-linear association between dietary live microbe and depression in individuals with gastrointestinal diseases, suggesting that higher intake levels may offer protective effects against depressive symptoms.
- 2 July 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 82, 101273
The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors
- 2 July 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 82, 101273
The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors
- Open Access
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1520766
Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) presents significant health challenges due to its aggressive nature and poor prognosis from late-stage diagnosis. Despite these challenges, emerging therapies like immune checkpoint inhibitors offer hope. β1-adrenergic signaling has been implicated in T cell exhaustion, which weakens the immune response in ESCC. Blocking this pathway could restore T cell function. Recent advances in single-cell RNA sequencing (scRNA-seq) have enabled deeper insights into tumor heterogeneity and the immune landscape, opening the door for personalized treatment strategies that may improve survival and reduce resistance to therapy.Methods: We combined scRNA-seq with bulk RNA analysis to explore adrenergic receptor signaling in ESCC, focusing on changes before and after neoadjuvant therapy. We identified ADRB1+ T cells through data analysis and experimental validation. Copy number variation (CNV) analysis detected malignant cells within scRNA-seq data, while intercellular interaction analysis examined communication between cell populations. Deconvolution of TCGA data revealed key immune populations, which were integrated into a prognostic model based on the adrenergic receptor signaling pathway and differentially expressed genes.Results: The adrenergic receptor signaling pathway was found in various immune cells, including T cells. scRNA-seq analysis revealed increased ADRB1 expression in T cells after neoadjuvant therapy. Immunofluorescence confirmed colocalization of ADRB1 with T cells, and fluorescence-activated cell sorting (FACS) showed that ADRB1 expression was elevated alongside exhaustion markers, while immune function markers were reduced. CNV analysis highlighted malignant cells in the tumor microenvironment, and intercellular interaction analysis explored ADRB1+ T cells’ role in immune support. Deconvolution of TCGA data identified ADRB1+ T cells, SPP1+ macrophages, and CD44+ malignant cells, all of which were prognostically significant. A prognostic model constructed from the intersection of the adrenergic receptor signaling pathway and differentially expressed genes following neoadjuvant therapy showed a significant prognostic effect.Conclusions: ADRB1 expression increases after neoadjuvant therapy in ESCC and correlates with poor prognosis. Our findings suggest ADRB1 as a potential prognostic biomarker and therapeutic target for post-neoadjuvant immunotherapy.
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1520766
Open AccessSingle-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) presents significant health challenges due to its aggressive nature and poor prognosis from late-stage diagnosis. Despite these challenges, emerging therapies like immune checkpoint inhibitors offer hope. β1-adrenergic signaling has been implicated in T cell exhaustion, which weakens the immune response in ESCC. Blocking this pathway could restore T cell function. Recent advances in single-cell RNA sequencing (scRNA-seq) have enabled deeper insights into tumor heterogeneity and the immune landscape, opening the door for personalized treatment strategies that may improve survival and reduce resistance to therapy.Methods: We combined scRNA-seq with bulk RNA analysis to explore adrenergic receptor signaling in ESCC, focusing on changes before and after neoadjuvant therapy. We identified ADRB1+ T cells through data analysis and experimental validation. Copy number variation (CNV) analysis detected malignant cells within scRNA-seq data, while intercellular interaction analysis examined communication between cell populations. Deconvolution of TCGA data revealed key immune populations, which were integrated into a prognostic model based on the adrenergic receptor signaling pathway and differentially expressed genes.Results: The adrenergic receptor signaling pathway was found in various immune cells, including T cells. scRNA-seq analysis revealed increased ADRB1 expression in T cells after neoadjuvant therapy. Immunofluorescence confirmed colocalization of ADRB1 with T cells, and fluorescence-activated cell sorting (FACS) showed that ADRB1 expression was elevated alongside exhaustion markers, while immune function markers were reduced. CNV analysis highlighted malignant cells in the tumor microenvironment, and intercellular interaction analysis explored ADRB1+ T cells’ role in immune support. Deconvolution of TCGA data identified ADRB1+ T cells, SPP1+ macrophages, and CD44+ malignant cells, all of which were prognostically significant. A prognostic model constructed from the intersection of the adrenergic receptor signaling pathway and differentially expressed genes following neoadjuvant therapy showed a significant prognostic effect.Conclusions: ADRB1 expression increases after neoadjuvant therapy in ESCC and correlates with poor prognosis. Our findings suggest ADRB1 as a potential prognostic biomarker and therapeutic target for post-neoadjuvant immunotherapy.
- Open Access
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1551259
High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer
Introduction: Identifying predictive biomarkers for immune checkpoint inhibitor (ICI) treatment is critical for gastric cancer (GC) prognosis. C-X-C motif chemokine ligand 13(CXCL13) plays an important role in immune regulation by binding exclusively to its receptor CXCR5. However, its role, underlying mechanisms, and prognostic significance in ICI-treated GC patients remain controversial.Methods: This study investigated the clinical significance of CXCL13 and its potential immunomodulatory function in GC patients. A total of 144 GC patients from two cohorts, who received a combination of chemotherapy and anti-PD-1 antibody, were analyzed. The expression of CXCL13 was assessed using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay. Associations between CXCL13, CXCR5, CD8, and CD4 were assessed by IHC and immunofluorescence. Survival analysis was performed using the Kaplan–Meier method and Cox proportional hazards model. The treatment response to CXCL13 and anti-PD-1 antibody was investigated using a subcutaneous xenograft tumor mouse model.Results: The results suggested that patients with high CXCL13 expression had prolonged survival. High CXCL13 expression exhibited increased infiltration of CXCR5+CD8+ T cells and was associated with better outcomes. The combined assessment of CXCL13, CXCR5, and CD8+ T cells served as an independent predictor of prognosis. Additionally, CXCR5 and CD8+ T cells were enriched in tertiary lymphoid structures (TLSs), which conferred a prognostic benefit in the presence of high CXCL13 expression. CXCL13, in combination with anti-PD-1 therapy, retarded tumor growth in vivo, resulting in increased infiltration of CXCR5+CD8+ T cells.Discussion: This study identified CXCL13 as a prognostic factor in GC patients receiving ICI therapy, emphasizing its critical role in the antitumor microenvironment via CXCR5+CD8+ T cells.
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1551259
Open AccessHigh expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer
Introduction: Identifying predictive biomarkers for immune checkpoint inhibitor (ICI) treatment is critical for gastric cancer (GC) prognosis. C-X-C motif chemokine ligand 13(CXCL13) plays an important role in immune regulation by binding exclusively to its receptor CXCR5. However, its role, underlying mechanisms, and prognostic significance in ICI-treated GC patients remain controversial.Methods: This study investigated the clinical significance of CXCL13 and its potential immunomodulatory function in GC patients. A total of 144 GC patients from two cohorts, who received a combination of chemotherapy and anti-PD-1 antibody, were analyzed. The expression of CXCL13 was assessed using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay. Associations between CXCL13, CXCR5, CD8, and CD4 were assessed by IHC and immunofluorescence. Survival analysis was performed using the Kaplan–Meier method and Cox proportional hazards model. The treatment response to CXCL13 and anti-PD-1 antibody was investigated using a subcutaneous xenograft tumor mouse model.Results: The results suggested that patients with high CXCL13 expression had prolonged survival. High CXCL13 expression exhibited increased infiltration of CXCR5+CD8+ T cells and was associated with better outcomes. The combined assessment of CXCL13, CXCR5, and CD8+ T cells served as an independent predictor of prognosis. Additionally, CXCR5 and CD8+ T cells were enriched in tertiary lymphoid structures (TLSs), which conferred a prognostic benefit in the presence of high CXCL13 expression. CXCL13, in combination with anti-PD-1 therapy, retarded tumor growth in vivo, resulting in increased infiltration of CXCR5+CD8+ T cells.Discussion: This study identified CXCL13 as a prognostic factor in GC patients receiving ICI therapy, emphasizing its critical role in the antitumor microenvironment via CXCR5+CD8+ T cells.
- Open Access
- 13 November 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1477427
A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer
Background: Platelets can dynamically regulate tumor development and progression. Nevertheless, research on the predictive value and specific roles of platelets in gastric cancer (GC) is limited. This research aims to establish a predictive platelets-related gene signature in GC with prognostic and therapeutic implications.Methods: We downloaded the transcriptome data and clinical materials of GC patients (n=378) from The Cancer Genome Atlas (TCGA) database. Prognostic platelets-related genes screened by univariate Cox regression were included in Least Absolute Shrinkage and Selection Operator (LASSO) analysis to construct a risk model. Kaplan-Meier curves and receiver operating characteristic curves (ROCs) were performed in the TCGA cohort and three independent validation cohorts. A nomogram integrating the risk score and clinicopathological features was constructed. Functional enrichment and tumor microenvironment (TME) analyses were performed. Drug sensitivity prediction was conducted through The Cancer Therapeutics Response Portal (CTRP) database. Finally, the expression of ten signature genes was validated by quantitative real-time PCR (qRT-PCR).Results: A ten-gene (SERPINE1, ANXA5, DGKQ, PTPN6, F5, DGKB, PCDH7, GNG11, APOA1, and TF) predictive risk model was finally constructed. Patients were categorized as high- or low-risk using median risk score as the threshold. The area under the ROC curve (AUC) values for the 1-, 2-, and 3-year overall survival (OS) in the training cohort were 0.670, 0.695, and 0.707, respectively. Survival analysis showed a better OS in low-risk patients in the training and validation cohorts. The AUCs of the nomogram for predicting 1-, 2-, and 3-year OS were 0.708, 0.763, and 0.742, respectively. TME analyses revealed a higher M2 macrophage infiltration and an immunosuppressive TME in the high-risk group. Furthermore, High-risk patients tended to be more sensitive to thalidomide, MK-0752, and BRD-K17060750.Conclusion: The novel platelets-related genes signature we identified could be used for prognosis and treatment prediction in GC.
- 13 November 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1477427
Open AccessA novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer
Background: Platelets can dynamically regulate tumor development and progression. Nevertheless, research on the predictive value and specific roles of platelets in gastric cancer (GC) is limited. This research aims to establish a predictive platelets-related gene signature in GC with prognostic and therapeutic implications.Methods: We downloaded the transcriptome data and clinical materials of GC patients (n=378) from The Cancer Genome Atlas (TCGA) database. Prognostic platelets-related genes screened by univariate Cox regression were included in Least Absolute Shrinkage and Selection Operator (LASSO) analysis to construct a risk model. Kaplan-Meier curves and receiver operating characteristic curves (ROCs) were performed in the TCGA cohort and three independent validation cohorts. A nomogram integrating the risk score and clinicopathological features was constructed. Functional enrichment and tumor microenvironment (TME) analyses were performed. Drug sensitivity prediction was conducted through The Cancer Therapeutics Response Portal (CTRP) database. Finally, the expression of ten signature genes was validated by quantitative real-time PCR (qRT-PCR).Results: A ten-gene (SERPINE1, ANXA5, DGKQ, PTPN6, F5, DGKB, PCDH7, GNG11, APOA1, and TF) predictive risk model was finally constructed. Patients were categorized as high- or low-risk using median risk score as the threshold. The area under the ROC curve (AUC) values for the 1-, 2-, and 3-year overall survival (OS) in the training cohort were 0.670, 0.695, and 0.707, respectively. Survival analysis showed a better OS in low-risk patients in the training and validation cohorts. The AUCs of the nomogram for predicting 1-, 2-, and 3-year OS were 0.708, 0.763, and 0.742, respectively. TME analyses revealed a higher M2 macrophage infiltration and an immunosuppressive TME in the high-risk group. Furthermore, High-risk patients tended to be more sensitive to thalidomide, MK-0752, and BRD-K17060750.Conclusion: The novel platelets-related genes signature we identified could be used for prognosis and treatment prediction in GC.